Physician profile
Charles E Hendrix
NPI 1437101128
$7,122.53
in general payments reported to CMS, 2019-2025
46 companies · $831 in 2025
The $831 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,600 · 2020: $1,574 · 2021: $733 · 2022: $853 · 2023: $772 · 2024: $761 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $769.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $690.51 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $595.06 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $547.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $481.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $455.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $447.37 | 2019-2025 | |
| Lilly USA, LLC | $415.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $228.78 | 2019-2020 | |
| Astellas Pharma US INC | $227.34 | 2019-2023 | Veozah |
| Abbvie INC. | $223.45 | 2019-2025 | |
| Amarin Pharma, INC. | $208.32 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.36 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $161.18 | 2024-2025 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $157.95 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.